Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 4497 | 38.2106 |
09:34 ET | 1500 | 38.31 |
09:36 ET | 100 | 38.365 |
09:38 ET | 915 | 38.3 |
09:39 ET | 1300 | 38.3 |
09:41 ET | 2355 | 38.67 |
09:43 ET | 2850 | 38.53 |
09:45 ET | 1675 | 38.6273 |
09:50 ET | 2508 | 38.92 |
09:52 ET | 331 | 38.92 |
09:54 ET | 1871 | 38.845 |
09:56 ET | 100 | 38.7201 |
09:57 ET | 100 | 38.77 |
09:59 ET | 2113 | 38.88 |
10:01 ET | 950 | 38.825 |
10:03 ET | 1400 | 38.615 |
10:06 ET | 1381 | 38.75 |
10:08 ET | 100 | 38.74 |
10:10 ET | 600 | 38.695 |
10:14 ET | 2501 | 38.68 |
10:15 ET | 5133 | 38.62 |
10:17 ET | 6288 | 38.49 |
10:19 ET | 1305 | 38.38 |
10:21 ET | 531 | 38.295 |
10:24 ET | 7623 | 38.71 |
10:26 ET | 2427 | 38.7601 |
10:28 ET | 700 | 38.84 |
10:30 ET | 400 | 38.8554 |
10:32 ET | 6961 | 39.04 |
10:33 ET | 2402 | 39.0788 |
10:35 ET | 1764 | 39.11 |
10:37 ET | 1243 | 38.98 |
10:39 ET | 2991 | 39.02 |
10:42 ET | 6193 | 39.04 |
10:44 ET | 1035 | 38.99 |
10:46 ET | 761 | 39.03 |
10:48 ET | 869 | 39.04 |
10:50 ET | 1710 | 39.13 |
10:51 ET | 300 | 39.12 |
10:53 ET | 200 | 39.125 |
10:55 ET | 800 | 39.125 |
10:57 ET | 839 | 39.17 |
11:00 ET | 931 | 39.1789 |
11:02 ET | 5950 | 39.12 |
11:04 ET | 671 | 39.12 |
11:06 ET | 1624 | 39.115 |
11:08 ET | 1238 | 39.125 |
11:09 ET | 10549 | 38.985 |
11:11 ET | 2225 | 38.95 |
11:13 ET | 1692 | 38.8729 |
11:15 ET | 1407 | 39.02 |
11:18 ET | 1170 | 38.9412 |
11:20 ET | 1050 | 38.969 |
11:22 ET | 100 | 38.99 |
11:24 ET | 613 | 39 |
11:26 ET | 9836 | 38.985 |
11:27 ET | 1837 | 39.05 |
11:29 ET | 150 | 39.03 |
11:31 ET | 1010 | 39 |
11:33 ET | 648 | 39.025 |
11:36 ET | 6605 | 39.01 |
11:38 ET | 1526 | 39.07 |
11:40 ET | 668 | 39.02 |
11:42 ET | 200 | 39.02 |
11:44 ET | 712 | 39.07 |
11:45 ET | 510 | 39.015 |
11:47 ET | 875 | 39.015 |
11:49 ET | 502 | 39.015 |
11:51 ET | 18618 | 38.86 |
11:54 ET | 3058 | 38.86 |
11:58 ET | 562 | 38.845 |
12:00 ET | 1941 | 38.84 |
12:02 ET | 9704 | 38.85 |
12:03 ET | 6190 | 38.855 |
12:05 ET | 2539 | 38.845 |
12:07 ET | 13411 | 38.815 |
12:09 ET | 12869 | 38.63 |
12:12 ET | 1236 | 38.63 |
12:14 ET | 472 | 38.625 |
12:16 ET | 2528 | 38.645 |
12:18 ET | 600 | 38.655 |
12:20 ET | 2940 | 38.74 |
12:21 ET | 7681 | 38.6 |
12:23 ET | 300 | 38.59 |
12:25 ET | 100 | 38.59 |
12:27 ET | 5341 | 38.58 |
12:30 ET | 737 | 38.58 |
12:32 ET | 500 | 38.58 |
12:34 ET | 4413 | 38.64 |
12:36 ET | 731 | 38.615 |
12:38 ET | 5792 | 38.685 |
12:39 ET | 300 | 38.7 |
12:41 ET | 200 | 38.68 |
12:43 ET | 3477 | 38.81 |
12:45 ET | 1932 | 38.91 |
12:48 ET | 200 | 38.91 |
12:50 ET | 701 | 38.91 |
12:52 ET | 908 | 38.93 |
12:54 ET | 5828 | 38.7 |
12:56 ET | 200 | 38.75 |
12:57 ET | 665 | 38.71 |
12:59 ET | 6442 | 38.7 |
01:01 ET | 550 | 38.675 |
01:03 ET | 2165 | 38.71 |
01:06 ET | 2403 | 38.705 |
01:08 ET | 5715 | 38.72 |
01:10 ET | 400 | 38.705 |
01:12 ET | 16004 | 38.7599 |
01:14 ET | 963 | 38.74 |
01:15 ET | 1100 | 38.735 |
01:17 ET | 467 | 38.73 |
01:19 ET | 1367 | 38.725 |
01:21 ET | 100 | 38.725 |
01:24 ET | 32917 | 38.665 |
01:26 ET | 1300 | 38.65 |
01:28 ET | 762 | 38.65 |
01:30 ET | 1465 | 38.605 |
01:32 ET | 1570 | 38.6125 |
01:33 ET | 3959 | 38.635 |
01:35 ET | 375 | 38.635 |
01:37 ET | 731 | 38.625 |
01:39 ET | 3224 | 38.73 |
01:42 ET | 300 | 38.7 |
01:44 ET | 53954 | 38.28 |
01:46 ET | 44026 | 37.93 |
01:48 ET | 6618 | 37.84 |
01:50 ET | 14321 | 37.655 |
01:51 ET | 4962 | 37.31 |
01:53 ET | 4209 | 37.35 |
01:55 ET | 930 | 37.265 |
01:57 ET | 9047 | 37.18 |
02:00 ET | 8075 | 37.14 |
02:02 ET | 2404 | 37.065 |
02:04 ET | 650 | 37.05 |
02:06 ET | 25459 | 37.41 |
02:08 ET | 2065 | 37.395 |
02:09 ET | 100 | 37.47 |
02:11 ET | 6054 | 37.62 |
02:13 ET | 2974 | 37.62 |
02:15 ET | 1845 | 37.69 |
02:18 ET | 5053 | 37.855 |
02:20 ET | 946 | 37.87 |
02:22 ET | 3318 | 37.83 |
02:24 ET | 1554 | 37.695 |
02:26 ET | 511 | 37.66 |
02:27 ET | 3634 | 37.66 |
02:29 ET | 236 | 37.6 |
02:31 ET | 11089 | 37.685 |
02:33 ET | 224 | 37.685 |
02:36 ET | 2090 | 37.59 |
02:38 ET | 1249 | 37.56 |
02:40 ET | 8784 | 37.495 |
02:42 ET | 3107 | 37.67 |
02:44 ET | 700 | 37.59 |
02:45 ET | 600 | 37.585 |
02:47 ET | 988 | 37.6 |
02:49 ET | 3486 | 37.66 |
02:51 ET | 2136 | 37.65 |
02:54 ET | 1878 | 37.685 |
02:56 ET | 3241 | 37.59 |
02:58 ET | 563 | 37.68 |
03:00 ET | 763 | 37.68 |
03:02 ET | 215 | 37.69 |
03:03 ET | 920 | 37.64 |
03:05 ET | 1147 | 37.645 |
03:07 ET | 5708 | 37.65 |
03:09 ET | 2563 | 37.65 |
03:12 ET | 3437 | 37.66 |
03:14 ET | 1500 | 37.545 |
03:16 ET | 4431 | 37.545 |
03:18 ET | 745 | 37.54 |
03:20 ET | 3091 | 37.32 |
03:21 ET | 3869 | 37.08 |
03:23 ET | 3950 | 37.185 |
03:25 ET | 3267 | 37.05 |
03:27 ET | 17188 | 37.125 |
03:30 ET | 600 | 37.13 |
03:32 ET | 9035 | 37.29 |
03:34 ET | 1872 | 37.29 |
03:36 ET | 2442 | 37.11 |
03:38 ET | 1567 | 36.945 |
03:39 ET | 6764 | 36.855 |
03:41 ET | 4532 | 36.93 |
03:43 ET | 4765 | 36.87 |
03:45 ET | 6935 | 36.975 |
03:48 ET | 6432 | 37.2 |
03:50 ET | 1187 | 37.175 |
03:52 ET | 4038 | 37.22 |
03:54 ET | 6657 | 37.22 |
03:56 ET | 13593 | 37.2 |
03:57 ET | 12004 | 37.25 |
03:59 ET | 16534 | 37.23 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.2B | -16.1x | --- |
CG Oncology Inc | 2.1B | -28.4x | --- |
Apogee Therapeutics Inc | 2.2B | -19.4x | --- |
Iovance Biotherapeutics Inc | 2.0B | -4.0x | --- |
Janux Therapeutics Inc | 2.1B | -32.2x | --- |
Vera Therapeutics Inc | 1.9B | -17.6x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -16.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.